{"id":2142,"date":"2026-10-03T14:31:15","date_gmt":"2026-10-03T14:31:15","guid":{"rendered":"https:\/\/xesi.net\/?p=2142"},"modified":"2026-10-03T14:31:15","modified_gmt":"2026-10-03T14:31:15","slug":"researchers-identify-key-enzyme-that-could-prevent-severe-liver-disease-progression","status":"publish","type":"post","link":"https:\/\/xesi.net\/?p=2142","title":{"rendered":"Researchers Identify Key Enzyme That Could Prevent Severe Liver Disease Progression"},"content":{"rendered":"

A team of researchers co-led by Cedars-Sinai Health Sciences University has uncovered a critical biological mechanism that may hold the key to protecting the liver from the devastating damage associated with the progression of common liver disease. The findings, detailed in a preclinical study published in the journal Nature Metabolism<\/em>, identify a specific enzyme\u2014UBE2N\u2014as a potential guardian against the transition from manageable fatty liver disease to life-threatening liver failure. This discovery offers a promising new direction for the development of therapeutic strategies aimed at halting the advancement of metabolic dysfunction-associated steatotic liver disease (MASLD).<\/p>\n

The Growing Crisis of Liver Disease<\/h3>\n

To understand the magnitude of this discovery, it is necessary to examine the prevalence of the condition it aims to address. According to data from the American Liver Foundation, an estimated 100 million people in the United States currently live with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition formerly known as nonalcoholic fatty liver disease. While many individuals may live with the initial stages of the disease without experiencing immediate, acute symptoms, the potential for long-term health complications is significant.<\/p>\n

The clinical concern arises when the condition shifts from a manageable state of fat accumulation to a more aggressive, inflammatory phase. Roughly 20% to 25% of individuals diagnosed with MASLD eventually progress to metabolic dysfunction-associated steatohepatitis (MASH). Unlike the earlier, milder forms of the disease, MASH is characterized by the presence of excess liver fat accompanied by systemic inflammation, ongoing cell injury, and the development of fibrosis, or scarring, within the liver tissue. If left unchecked, this cycle of inflammation and scarring can lead to cirrhosis, liver failure, and the need for organ transplantation.<\/p>\n

The Challenges of Managing MASH<\/h3>\n

The difficulty in treating MASH has long been a frustration for both clinicians and patients. Currently, the medical community\u2019s approach is primarily reactive rather than curative. Standard care centers on rigorous lifestyle modifications\u2014such as dietary changes, weight management, and physical activity\u2014aimed at reducing the metabolic load on the liver. While these efforts are essential for limiting further damage, they often prove insufficient to reverse existing inflammation or the scarring that has already taken hold.<\/p>\n

Although there are pharmaceutical interventions available to manage the underlying metabolic conditions that contribute to MASH, effective, curative treatments remain elusive. The lack of a definitive cure for MASH has left a significant gap in hepatology, as the medical community seeks ways to stop the disease in its tracks before permanent structural damage occurs. The complexity of the disease, which involves intricate interactions between metabolic health, cellular energy production, and the immune system, has made finding a singular therapeutic target exceptionally difficult.<\/p>\n

The Role of Mitochondrial Dysfunction<\/h3>\n

Recent scientific inquiry has increasingly focused on the role of mitochondria, the specialized structures within cells that act as power plants, providing the energy necessary for cellular function. In the context of liver health, earlier research has suggested that when mitochondria become damaged, they cease to function efficiently, potentially contributing to the onset and rapid progression of MASH. When these "power plants" fail, cells struggle to process fats, leading to an accumulation of lipids that triggers inflammation and cellular stress.<\/p>\n

In this new multicenter study, the researchers at Cedars-Sinai sought to identify what happens to the molecular machinery within these cells as MASH advances. Through rigorous investigation, the team discovered that levels of an enzyme known as UBE2N show a marked decline in liver cells as the disease progresses to more advanced stages. This inverse relationship\u2014the lower the levels of the enzyme, the more advanced the disease\u2014suggested to the scientists that UBE2N might play a protective role in maintaining liver health.<\/p>\n

"The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat," explained Ekihiro Seki, MD, PhD, a professor of Medicine and Biomedical Sciences at Cedars-Sinai and a co-corresponding author of the study. "When levels of the enzyme fell, we saw more damaged cells and injury to the liver. This suggested that the loss of UBE2N was not merely a byproduct of the disease, but rather a driving factor in the cellular degradation that defines MASH."<\/p>\n

Restoring Cellular Health in Preclinical Models<\/h3>\n

Following the identification of UBE2N\u2019s role, the research team sought to determine if restoring the enzyme could reverse or mitigate the damage observed in MASH. To test this hypothesis, the researchers employed laboratory mice as a preclinical model for the disease. By restoring UBE2N to normal, healthy levels in the livers of these mice, the team observed a significant improvement in the health of the organ.<\/p>\n

The results were compelling: the restoration of UBE2N led to a measurable reduction in fat accumulation, a decrease in inflammatory markers, and a mitigation of the scarring processes that typically characterize MASH. By essentially "rebooting" the cell’s ability to clean up damaged mitochondria and process fat effectively, the enzyme helped stabilize the liver\u2019s metabolic environment. These findings suggest that UBE2N could serve as a potential treatment target, offering a way to prevent the transition from simple MASLD to the more dangerous MASH.<\/p>\n

Future Implications for Clinical Care<\/h3>\n

The discovery of UBE2N\u2019s function represents a meaningful step forward in the molecular understanding of liver disease. It moves the conversation from general lifestyle management to the possibility of targeted molecular therapy that could preserve liver integrity before severe damage is permanent.<\/p>\n

"The identification of this enzyme’s role in regulating mitochondria in the liver is an important advance in understanding steatotic liver disease," said Shelly Lu, MD, the Women’s Guild Chair in Gastroenterology and director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai. "Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit, and lead to new therapeutic approaches for preventing advanced disease."<\/p>\n

While the path from preclinical study to human clinical trials is rigorous and lengthy, the identification of UBE2N provides researchers with a specific biological target. The focus of future studies will likely involve determining the best methods to safely restore UBE2N levels in human patients and identifying the specific biomarkers that could help doctors determine which patients are at the highest risk of experiencing a decline in this protective enzyme.<\/p>\n

The study involved a broad collaborative effort from multiple researchers. Additional Cedars-Sinai authors contributing to the study included Michitaka Matsuda, So Yeon Kim, Takashi Tsuchiya, and Yoon Seok Roh. The international scope of the research was further bolstered by a team of collaborators, including Feng Wang, Jin Lee, Jeong-Su Park, Meizhou Huang, Hwan Ma, Guoyan Sui, Zixiong Zhou, Xufeng Wu, Haram Lee, Soohwan Oh, Hanseul Park, Key-Hwan Lim, Chun-Woong Park, Sang-Bae Han, Jin Tae Hong, and Michael Karin.<\/p>\n

This research was supported by a diverse array of funding sources, underscoring the global interest in resolving the challenges posed by MASH. Financial support was provided by the National Research Foundation of Korea (grant nos. RS-2025-02273102 and RS-2025-02603096), the Regional Innovation System & Education (RISE) programme of Chungbuk (grant no. 2025-RISE-11-014-03), the Pinnacle Research Award of the American Association for the Study of Liver Diseases (AASLD), the San Diego Digestive Diseases Research Center (SDDRC) Pilot\/Feasibility Grant (NIDDK P30 DK120515), the National Institutes of Health (grant nos. R01DK085252, R01DK138591, and R01CA301632), and the National Natural Science Foundation of China (grant no. 82404726). <\/p>\n

As the medical community continues to grapple with the rising tide of metabolic disorders, findings like these offer a glimmer of hope. By uncovering the specific molecular pathways that guard against cellular failure, researchers are building the foundation for a future where MASH can be caught early, treated effectively, and potentially prevented entirely.<\/p>\n","protected":false},"excerpt":{"rendered":"

A team of researchers co-led by Cedars-Sinai Health Sciences University has uncovered a critical biological mechanism that may hold the key to protecting the liver from the devastating damage associated with the progression of common liver disease. The findings, detailed in a preclinical study published in the journal Nature Metabolism, identify a specific enzyme\u2014UBE2N\u2014as a […]<\/p>\n","protected":false},"author":1,"featured_media":2141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[370],"tags":[1474,3947,156,3949,61,3948,3027,653,371,2393,372],"class_list":["post-2142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science-and-nature","tag-disease","tag-enzyme","tag-identify","tag-liver","tag-nature","tag-prevent","tag-progression","tag-researchers","tag-science","tag-severe","tag-space"],"_links":{"self":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/2142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2142"}],"version-history":[{"count":0,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/2142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/media\/2141"}],"wp:attachment":[{"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}